EP0444549A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Imidazopyridazines their production and use
Assignee: Takeda Pharmaceutical Co Ltd
•
Filing: 1991-02-23
•
Granted: —
•
Expires: 2011-02-23
Abstract
Abstract An imidazo [1,2-b]pyridazine compound of the formula (I): wherein R₁ is a halogen atom or a lower alkyl group optionally having substituent(s), R₂ and R₃ are, independently, a hydrogen atom, a lower alkyl group optionally having substituent(s), a cycloalkyl group or a phenyl group optionally having substituent(s) or R₂ and R₃ together with the adjacent nitrogen atom to which they bond may form a heterocyclic ring optionally having substituent(s), X is an oxygen atom or S(O) k (k is zero to two), a group is a bivalent three to seven membered homocyclic or heterocyclic group optionally having substituent(s), m¹ and m² each is an integer of 0 to 4 and n is an integer of 0 or 1; or its salt, which is useful as antiasthmatics..
Inventors
- 👤 Akio Miyake
- 👤 Yasuko Ashida
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-02 13:15
CPC Classifications
C; C07; C07D; C07D487/00; C07D487/02; C07D487/04; A; A61; A61P; A61P11/00; A61P11/06; A61P11/08; A61P29/00; A61P37/00; A61P37/08
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
121 words
An imidazo [1,2-b]pyridazine compound of the formula (I): wherein R₁ is a halogen atom or a lower alkyl group optionally having substituent(s), R₂ and R₃ are, independently, a hydrogen atom, a lower alkyl group optionally having substituent(s), a cycloalkyl group or a phenyl group optionally having substituent(s) or R₂ and R₃ together with the adjacent nitrogen atom to which they bond may form a heterocyclic ring optionally having substituent(s), X is an oxygen atom or S(O) k (k is zero to two), a group is a bivalent three to seven membered homocyclic or heterocyclic group optionally having substituent(s), m¹ and m² each is an integer of 0 to 4 and n is an integer of 0 or 1; or its salt.
Claim 2
Dependent Claim
53 words
A compound of claim 1 in which a group of is a three to six membered cycloalkylene group, n is 0 or 1, R¹ is a lower alkyl group, X is an oxygen or sulfur atom, m¹ and m² are 1 or 2, and R² and R³ are hydrogen atoms or its salt.
Claim 3
Dependent Claim
41 words
A compound of claim 1 in which a group of is a three to six membered cycloalkylene group, n is 0, X is an oxygen atom, m¹ and m² are 1, and R² and R³ are hydrogen atoms, or its salt.
Claim 4
Dependent Claim
20 words
A compound of claim 2 or 3 in which the three to six membered cycloalkylene group is or its salt.
Claim 5
Dependent Claim
11 words
A compound of claim 1 which is 6-[(2,2-pentamethylene-3-sulfamoylpropyl)oxy]imidazo[1,2-b]pyridazine or its hydrochloride.
Claim 6
Dependent Claim
11 words
A compound of claim 1 is 6-[(2,2-tetramethylene-3-sulfamoylpropyl)oxy]imidazo [1,2-b]pyridazine or its hydrochloride.
Claim 7
Dependent Claim
118 words
A process for the production of a compound of the formula (I) in claim 1 or its salt, which comprises A) reacting a compound of the formula (II): or its salt with a compound of the formula (III): or its salt; B) reacting a compound of the formula (IV): or its salt with a compound of the formula (V): or its salt; or C) reacting a compound of the formula (VI): or its salt with an amine of the formula (VII): or its salt, wherein R¹, R₂, R₃, X, a group m¹, m² and n have the same meanings as defined in the formula (I), Y and Z is a reactive group and W is a halogen atom.
Claim 8
Dependent Claim
21 words
A process of claim 7 which is adopted to prepare a compound as claimed in any of claims 2 to 6.
Claim 9
Dependent Claim
27 words
An antiasthmatic composition which comprises a compound of the formula (I) claimed in claim 1 or its pharmaceutically acceptable salt and a pharmaceutically acceptable carrier or diluent.
Claim 10
Dependent Claim
22 words
A composition of claim 10 which comprises a compound claimed in any of claims 2 to 6 or its pharmaceutically acceptable salt.
Claim 11
Dependent Claim
24 words
A use of a compound of the formula (I) in claim 1 or its pharmaceutically acceptable salt in the preparation of an antiasthmatic composition.
References Cited (Backward Citations)
EP0225522A1
Cited
EP0305093A1
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.